Convenience is the key to hepatitis A and B vaccination uptake among young adult injection drug users

Jennifer V. Campbell, Richard S. Garfein, Hanne Thiede, Holly Hagan, Larry J. Ouellet, Elizabeth T. Golub, Sharon M. Hudson, Danielle C. Ompad, Cindy Weinbaum

Research output: Contribution to journalArticle

Abstract

Background: Despite CDC recommendations to vaccinate injection drug users (IDUs) against hepatitis A virus (HAV) and hepatitis B virus (HBV) infections, coverage remains low. Vaccination programs convenient to IDUs have not been widely implemented or evaluated. We assessed whether convenience and monetary incentives influenced uptake of free vaccine by 18-30-year-old IDUs in five U.S. cities. Methods: IDUs recruited from community settings completed risk behavior self-interviews and testing for antibodies to HAV (anti-HAV) and hepatitis B core antigen (anti-HBc). Vaccine was offered presumptively at pre-test (except in Chicago); on-site availability and incentives for vaccination differed by site, creating a quasi-experimental design. Results: Of 3181 participants, anti-HAV and anti-HBc seroprevalence was 19% and 23%, respectively. Although 83% of participants were willing to be vaccinated, only 36% received ≥1 dose, which varied by site: Baltimore (83%), Seattle (33%), Los Angeles (18%), New York (17%), and Chicago (2%). Participation was highest when vaccine was available immediately on-site and lowest when offered only after receiving results. Monetary incentives may have increased participation when on-site vaccination was not available. Conclusion: IDUs were willing to be vaccinated but immediate, on-site availability was critical for uptake. Convenience should be a key consideration in designing strategies to increase vaccine coverage among IDUs.

Original languageEnglish (US)
JournalDrug and Alcohol Dependence
Volume91
Issue numberSUPPL. 1
DOIs
StatePublished - Nov 2007

Fingerprint

Hepatitis A
vaccination
Drug Users
Hepatitis B
contagious disease
young adult
Young Adult
Vaccination
drug
Injections
Vaccines
Viruses
Pharmaceutical Preparations
Hepatitis A Antibodies
Hepatitis B Core Antigens
Motivation
incentive
coverage
Availability
Hepatitis A virus

Keywords

  • Hepatitis A virus
  • Hepatitis B virus
  • Injection drug use
  • Vaccination

ASJC Scopus subject areas

  • Medicine(all)
  • Behavioral Neuroscience
  • Toxicology
  • Health(social science)

Cite this

Convenience is the key to hepatitis A and B vaccination uptake among young adult injection drug users. / Campbell, Jennifer V.; Garfein, Richard S.; Thiede, Hanne; Hagan, Holly; Ouellet, Larry J.; Golub, Elizabeth T.; Hudson, Sharon M.; Ompad, Danielle C.; Weinbaum, Cindy.

In: Drug and Alcohol Dependence, Vol. 91, No. SUPPL. 1, 11.2007.

Research output: Contribution to journalArticle

Campbell, Jennifer V. ; Garfein, Richard S. ; Thiede, Hanne ; Hagan, Holly ; Ouellet, Larry J. ; Golub, Elizabeth T. ; Hudson, Sharon M. ; Ompad, Danielle C. ; Weinbaum, Cindy. / Convenience is the key to hepatitis A and B vaccination uptake among young adult injection drug users. In: Drug and Alcohol Dependence. 2007 ; Vol. 91, No. SUPPL. 1.
@article{65a711e59d7a40eba2bb31a7eea8235c,
title = "Convenience is the key to hepatitis A and B vaccination uptake among young adult injection drug users",
abstract = "Background: Despite CDC recommendations to vaccinate injection drug users (IDUs) against hepatitis A virus (HAV) and hepatitis B virus (HBV) infections, coverage remains low. Vaccination programs convenient to IDUs have not been widely implemented or evaluated. We assessed whether convenience and monetary incentives influenced uptake of free vaccine by 18-30-year-old IDUs in five U.S. cities. Methods: IDUs recruited from community settings completed risk behavior self-interviews and testing for antibodies to HAV (anti-HAV) and hepatitis B core antigen (anti-HBc). Vaccine was offered presumptively at pre-test (except in Chicago); on-site availability and incentives for vaccination differed by site, creating a quasi-experimental design. Results: Of 3181 participants, anti-HAV and anti-HBc seroprevalence was 19{\%} and 23{\%}, respectively. Although 83{\%} of participants were willing to be vaccinated, only 36{\%} received ≥1 dose, which varied by site: Baltimore (83{\%}), Seattle (33{\%}), Los Angeles (18{\%}), New York (17{\%}), and Chicago (2{\%}). Participation was highest when vaccine was available immediately on-site and lowest when offered only after receiving results. Monetary incentives may have increased participation when on-site vaccination was not available. Conclusion: IDUs were willing to be vaccinated but immediate, on-site availability was critical for uptake. Convenience should be a key consideration in designing strategies to increase vaccine coverage among IDUs.",
keywords = "Hepatitis A virus, Hepatitis B virus, Injection drug use, Vaccination",
author = "Campbell, {Jennifer V.} and Garfein, {Richard S.} and Hanne Thiede and Holly Hagan and Ouellet, {Larry J.} and Golub, {Elizabeth T.} and Hudson, {Sharon M.} and Ompad, {Danielle C.} and Cindy Weinbaum",
year = "2007",
month = "11",
doi = "10.1016/j.drugalcdep.2006.09.022",
language = "English (US)",
volume = "91",
journal = "Drug and Alcohol Dependence",
issn = "0376-8716",
publisher = "Elsevier Ireland Ltd",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Convenience is the key to hepatitis A and B vaccination uptake among young adult injection drug users

AU - Campbell, Jennifer V.

AU - Garfein, Richard S.

AU - Thiede, Hanne

AU - Hagan, Holly

AU - Ouellet, Larry J.

AU - Golub, Elizabeth T.

AU - Hudson, Sharon M.

AU - Ompad, Danielle C.

AU - Weinbaum, Cindy

PY - 2007/11

Y1 - 2007/11

N2 - Background: Despite CDC recommendations to vaccinate injection drug users (IDUs) against hepatitis A virus (HAV) and hepatitis B virus (HBV) infections, coverage remains low. Vaccination programs convenient to IDUs have not been widely implemented or evaluated. We assessed whether convenience and monetary incentives influenced uptake of free vaccine by 18-30-year-old IDUs in five U.S. cities. Methods: IDUs recruited from community settings completed risk behavior self-interviews and testing for antibodies to HAV (anti-HAV) and hepatitis B core antigen (anti-HBc). Vaccine was offered presumptively at pre-test (except in Chicago); on-site availability and incentives for vaccination differed by site, creating a quasi-experimental design. Results: Of 3181 participants, anti-HAV and anti-HBc seroprevalence was 19% and 23%, respectively. Although 83% of participants were willing to be vaccinated, only 36% received ≥1 dose, which varied by site: Baltimore (83%), Seattle (33%), Los Angeles (18%), New York (17%), and Chicago (2%). Participation was highest when vaccine was available immediately on-site and lowest when offered only after receiving results. Monetary incentives may have increased participation when on-site vaccination was not available. Conclusion: IDUs were willing to be vaccinated but immediate, on-site availability was critical for uptake. Convenience should be a key consideration in designing strategies to increase vaccine coverage among IDUs.

AB - Background: Despite CDC recommendations to vaccinate injection drug users (IDUs) against hepatitis A virus (HAV) and hepatitis B virus (HBV) infections, coverage remains low. Vaccination programs convenient to IDUs have not been widely implemented or evaluated. We assessed whether convenience and monetary incentives influenced uptake of free vaccine by 18-30-year-old IDUs in five U.S. cities. Methods: IDUs recruited from community settings completed risk behavior self-interviews and testing for antibodies to HAV (anti-HAV) and hepatitis B core antigen (anti-HBc). Vaccine was offered presumptively at pre-test (except in Chicago); on-site availability and incentives for vaccination differed by site, creating a quasi-experimental design. Results: Of 3181 participants, anti-HAV and anti-HBc seroprevalence was 19% and 23%, respectively. Although 83% of participants were willing to be vaccinated, only 36% received ≥1 dose, which varied by site: Baltimore (83%), Seattle (33%), Los Angeles (18%), New York (17%), and Chicago (2%). Participation was highest when vaccine was available immediately on-site and lowest when offered only after receiving results. Monetary incentives may have increased participation when on-site vaccination was not available. Conclusion: IDUs were willing to be vaccinated but immediate, on-site availability was critical for uptake. Convenience should be a key consideration in designing strategies to increase vaccine coverage among IDUs.

KW - Hepatitis A virus

KW - Hepatitis B virus

KW - Injection drug use

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=34648826276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34648826276&partnerID=8YFLogxK

U2 - 10.1016/j.drugalcdep.2006.09.022

DO - 10.1016/j.drugalcdep.2006.09.022

M3 - Article

VL - 91

JO - Drug and Alcohol Dependence

JF - Drug and Alcohol Dependence

SN - 0376-8716

IS - SUPPL. 1

ER -